NexGel Q2 2026: revenue $3.69M, net loss $2.87M; BioNX backlog $795K; proxy vote fails

NEXGEL, INC.

2026-Q2 EPS reported -$0.54 revenue$6,336,000

Q2 revenue $3.69M, net loss $2.87M; includes $756,554 BioNX amortization, $273,710 transaction costs, $144,495 SilverSeal recall.
BioNX Surgical backlog ~$795K due to supply chain; Sequence transferring manufacturing to San Antonio, TX.
Proxy vote failed to increase authorized shares/reverse split; will resolicit standalone, engaged Alliance Advisors, target late Sept.
$710K restricted cash from ATW Partners released and returned post-quarter; relationship concluded.
Launched BioNX Regenerative Eye Health & Aesthetics, led by Shaun Mullen; SilverSeal recall supports hospital launch in August.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.